KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LATâ„¢) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LATâ„¢ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.
View Top Employees from KemPharm, Inc.Website | http://www.kempharm.com |
Ticker | KMPH |
Revenue | $365000 |
Funding | $182.1 million |
Employees | 41 (23 on RocketReach) |
Founded | 2006 |
Address | 1180 Celebration Boulevard, Celebration, Florida 34747, US |
Phone | (319) 665-2575 |
Fax | (319) 665-2577 |
Technologies |
JavaScript,
HTML,
PHP
+38 more
(view full list)
|
Industry | Pharmaceuticals, Biotechnology, Drug Manufacturing & Research, Science and Engineering, Healthcare, Pharmaceutical, Health Care, Therapeutics |
Web Rank | 3 Million |
Keywords | Kempharm, Kem Pharma, Methylphenidate Prodrug, Abuse Trial Kempharm, Kmph |
Competitors | Minerva Neurosciences, QRxPharma, Soligenix, Inc., TARIS Bio, UroGen Pharma (formerly TheraCoat) |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular KemPharm, Inc. employee's phone or email?
The KemPharm, Inc. annual revenue was $365000 in 2024.
Rene Braeckman is the Vice President of Clinical Development of KemPharm, Inc..
23 people are employed at KemPharm, Inc..
KemPharm, Inc. is based in Celebration, Florida.
The NAICS codes for KemPharm, Inc. are [3254, 32541, 32, 325].
The SIC codes for KemPharm, Inc. are [283, 28].